TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

604

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

October 31, 2011

Conditions
HIV Infection
Interventions
DRUG

LPV/rtv

One 400mg LPV tablet twice daily with 100mg RTV

DRUG

TMC114/rtv

Two 300mg TMC114 tablets twice daily with 100mg RTV

Trial Locations (103)

Unknown

Phoenix

Little Rock

Beverly Hills

Long Beach

Los Angeles

San Francisco

West Hollywood

Denver

Washington D.C.

Fort Lauderdale

Miami

Orlando

Safety Harbor

Tampa

Vero Beach

Atlanta

Macon

Chicago

Boston

Berkley

Camden

East Orange

Newark

The Bronx

Durham

Huntersville

Winston-Salem

Cleveland

Portland

Philadelphia

Columbia

Austin

Dallas

Galveston

Houston

Longview

Hampton

Seattle

Milwaukee

Buenos Aires

Córdoba

Rosario

Darlinghurst

Melbourne

Perth

Surry Hills

Vienna

Antwerp

Brussels

Curitiba

Distrito Barao Geraldo-Campina

Nova Iguaçu

Pinheiros

Rio de Janeiro

São Paulo

Calgary

Ottawa

Toronto

Montreal

Providencia

Santiago

Aalborg

Nice

Paris

Rennes

Villejuif

Aachen

Berlin

Cologne

Düsseldorf

Hamburg

Mannheim

Osnabrück

Stuttgart

Melissia-Athens

Guatemala City

Budapest

Kuala Lumpur

Sungai Buloh

Guadalajara

Amsterdam

Groningen

Rotterdam

Panama City

Lisbon

Porto

San Juan

Kazan'

Moscow

Nizhny Novgorod

Saint Petersburg

Volgograd

Cape Town

Durban

Houghton, Johannesburg

Johannesburg

Pretoria

Barcelona

Madrid

Zurich

Bangkok

Khon Kaen

London

All Listed Sponsors
lead

Tibotec Pharmaceuticals, Ireland

INDUSTRY

NCT00110877 - TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients | Biotech Hunter | Biotech Hunter